Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 1
2016 2
2017 7
2018 7
2019 13
2020 10
2021 7
2022 10
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. Among authors: delozier am. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL. Reich K, et al. Among authors: delozier am. JAMA Dermatol. 2020 Dec 1;156(12):1333-1343. doi: 10.1001/jamadermatol.2020.3260. JAMA Dermatol. 2020. PMID: 33001140 Free PMC article. Clinical Trial.
Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.
King BA, Mesinkovska NA, Craiglow B, Kindred C, Ko J, McMichael A, Shapiro J, Goh C, Mirmirani P, Tosti A, Hordinsky M, Huang KP, Castelo-Soccio L, Bergfeld W, Paller AS, Mackay-Wiggan J, Glashofer M, Aguh C, Piliang M, Yazdan P, Lo Sicco K, Cassella JV, Koenigsberg J, Ahluwalia G, Ghorayeb E, Fakharzadeh S, Napatalung L, Gandhi K, DeLozier AM, Nunes FP, Senna MM. King BA, et al. Among authors: delozier am. J Am Acad Dermatol. 2022 Feb;86(2):359-364. doi: 10.1016/j.jaad.2021.08.043. Epub 2021 Aug 30. J Am Acad Dermatol. 2022. PMID: 34474079 Free article.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Wallace DJ, et al. Among authors: delozier am. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Lancet. 2018. PMID: 30043749 Clinical Trial.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes FP, Paller AS. Simpson E, et al. Among authors: delozier am. J Am Acad Dermatol. 2020 Sep;83(3):839-846. doi: 10.1016/j.jaad.2020.04.104. Epub 2020 Apr 25. J Am Acad Dermatol. 2020. PMID: 32344071
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, Reich K. Silverberg JI, et al. Among authors: delozier am. JAMA Dermatol. 2021 Jun 1;157(6):691-699. doi: 10.1001/jamadermatol.2021.1273. JAMA Dermatol. 2021. PMID: 33978711 Free PMC article. Clinical Trial.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Simpson EL, et al. Among authors: delozier am. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. Br J Dermatol. 2020. PMID: 31995838
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, Ghislain PD, Dutronc Y, Liao R, Yang FE, Brinker D, DeLozier AM, Meskimen E, Janes JM, Eyerich K; BREEZE-AD4 study group. Bieber T, et al. Among authors: delozier am. Br J Dermatol. 2022 Sep;187(3):338-352. doi: 10.1111/bjd.21630. Epub 2022 Jul 20. Br J Dermatol. 2022. PMID: 35484697 Clinical Trial.
Clinical Relevance of Skin Pain in Atopic Dermatitis.
Ständer S, Simpson EL, Guttman-Yassky E, Thyssen JP, Kabashima K, Ball SG, Rueda MJ, DeLozier AM, Silverberg JI. Ständer S, et al. Among authors: delozier am. J Drugs Dermatol. 2020 Oct 1;19(10):921-926. doi: 10.36849/JDD.2020.5498. J Drugs Dermatol. 2020. PMID: 33026764 Review.
50 results